| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg | |||
| 100mg | |||
| 250mg | |||
| Other Sizes |
Purity: ≥98%
| Targets |
p65
Armepavine inhibits TNF-α-induced MAPK and NF-κB signaling cascades. By targeting these pathways, it exerts anti-inflammatory and immunosuppressive effects. The specific molecular target is not identified but involves modulation of key inflammatory signaling pathways. Armepavine exerts anti-inflammatory effects on human peripheral blood mononuclear cells and immunosuppressive effects on T lymphocytes and mice with lupus nephritis. |
|---|---|
| ln Vitro |
Armepavine exerts anti-inflammatory effects on human peripheral blood mononuclear cells. It inhibits TNF-α-induced MAPK and NF-κB signaling cascades. The compound also shows immunosuppressive effects on T lymphocytes. It has demonstrated antifibrotic effects in vitro and in vivo. Armepavine exerts anti-inflammatory effects on human peripheral blood mononuclear cells and immunosuppressive effects on T lymphocytes and mice with lupus nephritis.
|
| ln Vivo |
Armepavine has been shown to have immunosuppressive effects in mice with lupus nephritis. It also exerts antifibrotic effects in rats. These in vivo activities support its potential for treating autoimmune and fibrotic diseases. Armepavine exerts anti-inflammatory effects on human peripheral blood mononuclear cells and immunosuppressive effects on T lymphocytes and mice with lupus nephritis.
|
| Enzyme Assay |
Specific protocols for in vitro enzyme/receptor binding assays for Armepavine are not detailed in the provided references. Its activity is assessed through its effects on cell signaling pathways, such as the inhibition of MAPK and NF-κB. Armepavine inhibits TNF-α-induced MAPK and NF-κB signaling cascades.
|
| Cell Assay |
Cellular assays for Armepavine involve treating cells like human peripheral blood mononuclear cells and T lymphocytes with the compound. The effects on inflammation and immune function are then measured. The compound's ability to inhibit TNF-α-induced signaling is also evaluated. Armepavine exerts anti-inflammatory effects on human peripheral blood mononuclear cells and immunosuppressive effects on T lymphocytes.
|
| Animal Protocol |
In vivo animal model protocols for Armepavine involve its administration to disease models. It has been studied in mice with lupus nephritis, where it showed immunosuppressive effects. It has also been evaluated in rat models of fibrosis. Armepavine has been shown to have immunosuppressive effects in mice with lupus nephritis.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for Armepavine is not available in the provided references. As a natural product, its PK properties would need to be evaluated in preclinical studies.
|
| Toxicity/Toxicokinetics |
Specific toxicological data for Armepavine is not available in the provided references. As a natural product, its safety profile would need to be evaluated in toxicology studies.
|
| References | |
| Additional Infomation |
Amipravine belongs to the isoquinoline class of compounds. (-)-Amipravine has been reported in poppies, discaria, and other organisms with available data.
Armepavine is a research compound not approved for clinical use. It is a natural product with anti-inflammatory, immunosuppressive, and antifibrotic activities. It is used to study the role of MAPK and NF-κB signaling in inflammation and immune regulation. Armepavine is a bioactive compound isolated from Nelumbo nucifera. |
| Molecular Formula |
C19H23NO3
|
|---|---|
| Molecular Weight |
313.397
|
| Exact Mass |
313.168
|
| Elemental Analysis |
C, 72.82; H, 7.40; N, 4.47; O, 15.32
|
| CAS # |
524-20-9
|
| Related CAS # |
524-20-9
|
| PubChem CID |
442169
|
| Appearance |
White to off-white solid powder
|
| Density |
1.151g/cm3
|
| Boiling Point |
460.5ºC at 760 mmHg
|
| Melting Point |
149-150 °C
|
| Flash Point |
232.3ºC
|
| Index of Refraction |
1.584
|
| LogP |
3.119
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
23
|
| Complexity |
370
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CN1CCC2=CC(=C(C=C2C1CC3=CC=C(C=C3)O)OC)OC
|
| InChi Key |
ZBKFZIUKXTWQTP-QGZVFWFLSA-N
|
| InChi Code |
InChI=1S/C19H23NO3/c1-20-9-8-14-11-18(22-2)19(23-3)12-16(14)17(20)10-13-4-6-15(21)7-5-13/h4-7,11-12,17,21H,8-10H2,1-3H3/t17-/m1/s1
|
| Chemical Name |
4-[[(1R)-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-1-yl]methyl]phenol
|
| Synonyms |
(-)-Armepavine; Evoeuropine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~319.1 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.98 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.98 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.98 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1908 mL | 15.9541 mL | 31.9081 mL | |
| 5 mM | 0.6382 mL | 3.1908 mL | 6.3816 mL | |
| 10 mM | 0.3191 mL | 1.5954 mL | 3.1908 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
